Online now: Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy
Therapeutic monoclonal antibodies are central to cancer treatment but often show incomplete efficacy. Cheng et al. demonstrate that transient host-cell glycoengineering to reduce N-glycan trimming strengthens IgG-FcγRIIIa bond resilience under vascular flow forces and potentiates therapeutic antibody efficacy in lymphoma and melanoma models. This study establishes force durability as an optimization parameter for therapeutic antibodies beyond the affinity-centric paradigm.
